139 related articles for article (PubMed ID: 38779355)
1. Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation.
Auner S; Hillebrand C; Boehm PM; Boecker J; Koren D; Schwarz S; Kovacs Z; Murakoezy G; Fischer G; Aigner C; Hoetzenecker K; Jaksch P; Benazzo A
Transpl Int; 2024; 37():12774. PubMed ID: 38779355
[TBL] [Abstract][Full Text] [Related]
2. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
[TBL] [Abstract][Full Text] [Related]
5. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: A single-center retrospective study.
Liu W; Zhao J; Kang ZY; Xiao YL; Yang L; Liu C; Li DH
Transpl Immunol; 2021 Oct; 68():101430. PubMed ID: 34147608
[TBL] [Abstract][Full Text] [Related]
6. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
7. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
[TBL] [Abstract][Full Text] [Related]
8. Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation.
Gochi F; Chen-Yoshikawa TF; Kayawake H; Ohsumi A; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Hamaji M; Yurugi K; Hishida R; Date H
J Heart Lung Transplant; 2021 Jul; 40(7):607-613. PubMed ID: 34078558
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
[TBL] [Abstract][Full Text] [Related]
10. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
12. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
13. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
[TBL] [Abstract][Full Text] [Related]
14. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
[TBL] [Abstract][Full Text] [Related]
15. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
[TBL] [Abstract][Full Text] [Related]
16. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
Cioni M; Nocera A; Innocente A; Tagliamacco A; Trivelli A; Basso S; Quartuccio G; Fontana I; Magnasco A; Drago F; Gurrado A; Guido I; Compagno F; Garibotto G; Klersy C; Verrina E; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
J Immunol Res; 2017; 2017():1747030. PubMed ID: 28367453
[TBL] [Abstract][Full Text] [Related]
17. Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death.
Keller M; Yang S; Ponor L; Bon A; Cochrane A; Philogene M; Bush E; Shah P; Mathew J; Brown AW; Kong H; Charya A; Luikart H; Nathan SD; Khush KK; Jang M; Agbor-Enoh S
Am J Transplant; 2023 Apr; 23(4):559-564. PubMed ID: 36732088
[TBL] [Abstract][Full Text] [Related]
18. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
20. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]